Is Sagimet Biosciences Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Sagimet Biosciences Inc (SGMT) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Sagimet Biosciences Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Sagimet Biosciences Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Sagimet Biosciences Inc?

Muslim investors may consider investing in Sagimet Biosciences Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Sagimet Biosciences Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Sagimet Biosciences Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Sagimet Biosciences Inc updated?

The Shariah compliance status of Sagimet Biosciences Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Sagimet Biosciences Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Sagimet Biosciences Inc?

You can check the latest Shariah compliance status of Sagimet Biosciences Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

SGMT Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 12, 2026

Report Source: 2025 Annual Report

Sagimet Biosciences Inc. Stock Analysis SGMT

United States Health Care Small Cap Report: 2025 Annual

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. The company is headquartered in San Mateo, California and currently employs 16 full-time employees. The company went IPO on 2023-07-14. The firm's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The firm is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.

Key Statistics of Sagimet Biosciences Inc (SGMT)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$6.89$7.34

Today's Open

$7.26

Volume

744.64K

P/E Ratio (TTM)

52 Week Range

$3.08$11.41

Market Cap

472.34M

Avg. Volume

3.10M

Dividend Yield

Financial Metrics & Statements of Sagimet Biosciences Inc (SGMT)

FAQ's for Sagimet Biosciences Inc (SGMT)

According to Musaffa’s Shariah screening methodology, Sagimet Biosciences Inc (SGMT) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.